News

Investor's Business Daily on MSN1mon
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
The drug works by activating Kv7, a channel that regulates electrical impulses and neurotransmitter release between neurons. The approach hasn't been validated in bipolar mania. The "lowest risk ...
TipRanks on MSN9d
Biohaven to present 13 abstracts at 2025 AAN annual meeting
Biohaven (BHVN) announced that it will present 13 abstracts at the 2025 American Academy of Neurology, AAN, Annual Meeting, taking place from ...